Key Takeaways:
Organon & Co. won US Food and Drug Administration approval to expand TOFIDENCE, its tocilizumab biosimilar, to treat severe cytokine release syndrome and certain hospitalized Covid-19 patients, broadening the drug's reach into critical-care settings.
"Expanding access to treatments for critical conditions like CRS is an important step in improving patient outcomes," Kevin Ali, chief executive officer of Organon, said in a statement.
The supplemental biologics license application covers adults and pediatric patients aged two years and older with CAR T cell-induced severe or life-threatening CRS, as well as hospitalized Covid-19 patients receiving systemic corticosteroids who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. TOFIDENCE, launched in May 2024, was already approved for rheumatoid arthritis, giant cell arteritis and two forms of juvenile idiopathic arthritis, making it the first tocilizumab biosimilar available in the US across a broad range of autoimmune and acute inflammatory indications.
The expanded label strengthens Organon's biosimilar portfolio at a time when the company faces pressure on legacy women's health products and aging brands. Shares rose 0.5% on the news and have surged 87.6% year to date, giving the company a market capitalization of $3.51 billion. The biosimilars market is valued at $47.36 billion in 2026 and is expected to grow at a compound annual rate of 16.84% through 2035, according to Precedence Research.
The approval comes as Organon pursues a $11.75 billion acquisition by Sun Pharmaceutical Industries, with shareholders set to receive $14.00 per share — a 103% premium to the stock's closing price on April 9. The deal, approved by both boards, is expected to close in early 2027. Separately, Organon and Shanghai Henlius Biotech won European approval in April for POHERDY, the first pertuzumab biosimilar approved in Europe for HER2-positive breast cancer.
For Organon holders, the TOFIDENCE label expansion reinforces the biosimilar growth narrative but does not alter the near-term focus on the Sun Pharma acquisition, expected to close in early 2027. Investors will watch for integration details and whether the combined entity can sustain the biosimilar momentum against generic pressure on legacy products.
This article is for informational purposes only and does not constitute investment advice.
